HUE042490T2 - 1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák - Google Patents

1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák

Info

Publication number
HUE042490T2
HUE042490T2 HUE11848865A HUE11848865A HUE042490T2 HU E042490 T2 HUE042490 T2 HU E042490T2 HU E11848865 A HUE11848865 A HU E11848865A HU E11848865 A HUE11848865 A HU E11848865A HU E042490 T2 HUE042490 T2 HU E042490T2
Authority
HU
Hungary
Prior art keywords
amino acid
molecules modified
analogue molecules
cyclosporine analogue
cyclosporine
Prior art date
Application number
HUE11848865A
Other languages
English (en)
Inventor
Alexander Hegmans
Bruce Fenske
Dan Trepanier
Mark Abel
Shin Sugiyama
Daren R Ure
Original Assignee
Contravir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contravir Pharmaceuticals Inc filed Critical Contravir Pharmaceuticals Inc
Publication of HUE042490T2 publication Critical patent/HUE042490T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
HUE11848865A 2010-12-15 2011-12-14 1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák HUE042490T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42357610P 2010-12-15 2010-12-15

Publications (1)

Publication Number Publication Date
HUE042490T2 true HUE042490T2 (hu) 2019-07-29

Family

ID=46243924

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11848865A HUE042490T2 (hu) 2010-12-15 2011-12-14 1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák

Country Status (25)

Country Link
US (2) US9200038B2 (hu)
EP (2) EP2651965B1 (hu)
JP (3) JP6144627B2 (hu)
KR (3) KR102305423B1 (hu)
CN (2) CN103443119B (hu)
AU (1) AU2011342284C1 (hu)
BR (1) BR112013014890B1 (hu)
CA (1) CA2821009C (hu)
DK (1) DK2651965T3 (hu)
ES (1) ES2705750T3 (hu)
HK (1) HK1243633A1 (hu)
HR (1) HRP20190096T1 (hu)
HU (1) HUE042490T2 (hu)
IL (1) IL226792A (hu)
LT (1) LT2651965T (hu)
MX (1) MX353720B (hu)
MY (2) MY165152A (hu)
NZ (1) NZ611620A (hu)
PL (1) PL2651965T3 (hu)
PT (1) PT2651965T (hu)
RU (1) RU2630690C9 (hu)
SG (2) SG10201510236XA (hu)
SI (1) SI2651965T1 (hu)
TR (1) TR201900128T4 (hu)
WO (1) WO2012079172A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JP6144627B2 (ja) * 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク. アミノ酸1および3で修飾されたシクロスポリン類似体分子
CN104487449A (zh) * 2012-06-01 2015-04-01 阿勒根公司 环孢菌素a类似物
EP2961767B1 (en) * 2013-03-01 2018-09-26 UCL Business PLC Non-immunosuppressive cyclosporin derivatives as antiviral agents
EP3038626A4 (en) * 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
EP3458470A4 (en) * 2016-05-17 2020-04-22 S&T Global Inc. NEW CYCLOSPOR DERIVATIVES AND USES THEREOF
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
AU2017378406A1 (en) 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US20180296588A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
WO2018193114A1 (en) 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Triphenylphosphonium-tethered tetracycyclines for use in treating cancer
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3840769A4 (en) * 2018-08-22 2022-06-22 Bacainn Biotherapeutics, Ltd. CYCLOSPORINE COMPOSITIONS AND METHODS OF USE
BR112022016960A2 (pt) * 2020-02-25 2022-10-25 Hepion Pharmaceuticals Inc Uso de análogos de ciclosporina para tratamento de câncer
CN115315432A (zh) * 2020-03-26 2022-11-08 睿诺医疗科技(上海)有限公司 亲环蛋白抑制剂及其用途
CA3199530A1 (en) * 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents
CN113173974A (zh) 2021-03-18 2021-07-27 北京大学深圳研究生院 环孢素衍生物的合成方法
CN115677533B (zh) * 2021-07-30 2023-12-05 沈阳化工研究院有限公司 一种4-庚基苯甲腈的制备方法

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (hu) 1975-11-04 1979-12-28 Sandoz Ag
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
EP0034567B1 (en) 1980-02-14 1984-11-07 Sandoz Ag A method for the total synthesis of cyclosporins and novel cyclosporins
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS6182786A (ja) 1984-09-28 1986-04-26 ブラザー工業株式会社 ミシン
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
ES2059558T3 (es) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
DE3851268T2 (de) 1987-06-19 1995-01-26 Sandoz Ag Zyklische Peptolide.
DE3888357T2 (de) 1987-06-22 1994-09-15 Merck & Co Inc Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en) 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5604092A (en) 1988-12-05 1997-02-18 The Trustees Of Columbia University In The City Of New York Method for the detection of HIV-1 using a cyclosporine-specific monoclonal antibody that reacts with the P24 Gag protein
AU4958590A (en) 1988-12-05 1990-07-10 Trustees Of Columbia University In The City Of New York, The Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5214130A (en) 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
DK0484281T4 (da) 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
GB9204466D0 (en) 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
WO1997011092A1 (fr) 1994-04-07 1997-03-27 Nippon Shinyaku Co., Ltd. Derives de phosphates de cyclosporine et composition medicinale
US5639852A (en) 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
JPH08148407A (ja) 1994-11-21 1996-06-07 Nikon Corp 照明光学装置
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
KR100241643B1 (ko) 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
KR100441220B1 (ko) 1995-07-17 2005-02-24 체-헴 아게 항-hiv효과를갖는사이클로스포린유도체
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US6270957B1 (en) 1997-08-26 2001-08-07 Wisconsin Alumni Research Foundation Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
AU8918998A (en) 1997-08-26 1999-03-16 Wisconsin Alumni Research Foundation Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ATE423130T1 (de) 1997-10-08 2009-03-15 Isotechnika Inc Deuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agenzien
US5990274A (en) 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
IL139825A0 (en) 1998-06-12 2002-02-10 Chem Ag C Novel cyclosporins
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
DE69928938T2 (de) 1998-07-01 2006-08-17 Debiopharm S.A. Neues cyclosporin mit verbesserter wirkung
ES2267492T3 (es) 1999-02-05 2007-03-16 Debiopharm S.A. Derivados de ciclosporina y procedimiento de preparacion de dichos derivados.
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
AU1420801A (en) 1999-11-19 2001-05-30 Lg Household & Health Care Ltd. Use of nonimmunosuppressive cyclosporin derivatives for hair growth
KR20020039528A (ko) 2000-11-22 2002-05-27 조명재 사이클로스포린 7- 티오아미드 유도체를 유효성분으로하는 모발성장촉진제
KR100360716B1 (ko) 2000-11-22 2002-11-13 주식회사 엘지생활건강 사이클로스포린 에이 7- 티오아미드 유도체를유효성분으로 하는 모발성장촉진제
KR100681670B1 (ko) 2001-02-14 2007-02-09 주식회사 엘지생활건강 [감마 히드록시 엔- 메틸-엘-루신9]사이클로스포린 에이를유효성분으로 하는 모발 성장 촉진제
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
JP4588979B2 (ja) 2001-04-20 2010-12-01 オプタルモファーマ アクチェンゲゼルシャフト プロドラッグとして使用されうる修飾型シクロスポリン及びその使用
KR100465012B1 (ko) 2001-05-11 2005-01-13 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
KR100695611B1 (ko) 2001-05-17 2007-03-14 주식회사 엘지생활건강 [감마 히드록시 엔-메틸 엘-루신4] 사이클로스포린유도체를 유효성분으로 하는 모발 성장 촉진제
US20030087813A1 (en) 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
BR0213661A (pt) 2001-10-19 2004-10-26 Isotechnika Inc Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica
ES2310604T3 (es) 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
DK1436321T3 (da) 2001-10-19 2006-11-13 Isotechnika Inc Syntese af cyclosporinanaloger
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR100641295B1 (ko) * 2002-11-11 2006-10-31 김성수 사이클로필린의 항산화제로서의 용도 및 사이클로필린의과발현에 의해 세포이식에서 사이클로스포린 a에 의해유발되는 세포독성의 방지
US20040110666A1 (en) 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
AU2004222306A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
ITMI20030627A1 (it) 2003-03-31 2004-10-01 Polimeri Europa Spa Polimeri vinilaromatici espandibili e procedimento per la loro preparazione.
TW200505946A (en) 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
NZ542882A (en) * 2003-04-11 2007-10-26 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US20040266669A1 (en) 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DE102004011988A1 (de) 2004-03-11 2005-09-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate und diese enthaltende pharmazeutische Zusammensetzungen
US20060015374A1 (en) 2004-07-19 2006-01-19 Yanhong Ochs Risk management on the application of crop inputs
CA2575280C (en) 2004-07-29 2012-08-14 Amr Technology, Inc. Novel processes for stereoselective synthesis of trans isatx 247
US20060035821A1 (en) 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US7226906B2 (en) 2004-08-16 2007-06-05 Array Biopharma, Inc. Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
MX2007003538A (es) 2004-10-01 2008-01-16 Scynexis Inc Derivados de ciclosporina 3-eter y 3-tioeter sustituidos para el tratamiento y prevencion de infeccion de hepatitis c.
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
ATE412005T1 (de) 2004-11-22 2008-11-15 Astellas Pharma Inc Zyklosporinanalog
MX2007007262A (es) 2004-12-17 2007-10-19 Isotechnika Inc Metabolitos de analogos de ciclosporina.
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
US20070232532A1 (en) 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
EP2313157A2 (en) * 2008-07-10 2011-04-27 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
AU2009276241A1 (en) 2008-07-30 2010-02-04 Ciclofilin Pharmaceuticals Corp. Nonimmunosuppressive cyclosporine analogue molecules
NZ594755A (en) 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US20100305047A1 (en) * 2009-05-27 2010-12-02 Allergan, Inc. Cyclosporin derivatives for enhancing the growth of hair
WO2011082289A1 (en) * 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
EP2627664B1 (en) * 2010-10-12 2018-04-04 Allergan, Inc. Cyclosporin analogs
JP5805773B2 (ja) * 2010-10-12 2015-11-10 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンアナログ
JP6144627B2 (ja) * 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク. アミノ酸1および3で修飾されたシクロスポリン類似体分子

Also Published As

Publication number Publication date
AU2011342284C1 (en) 2017-07-13
WO2012079172A1 (en) 2012-06-21
PT2651965T (pt) 2019-01-28
SG10201510236XA (en) 2016-01-28
RU2630690C2 (ru) 2017-09-12
US20160207961A1 (en) 2016-07-21
CN103443119A (zh) 2013-12-11
JP6831259B2 (ja) 2021-02-17
ES2705750T3 (es) 2019-03-26
HRP20190096T1 (hr) 2019-02-22
LT2651965T (lt) 2019-01-10
NZ611620A (en) 2016-02-26
PL2651965T3 (pl) 2019-04-30
AU2011342284A1 (en) 2013-07-18
EP3461835A1 (en) 2019-04-03
MY165152A (en) 2018-02-28
KR20130124515A (ko) 2013-11-14
CN107496902B (zh) 2022-01-18
RU2013127162A (ru) 2015-06-10
DK2651965T3 (en) 2019-02-18
CA2821009A1 (en) 2012-06-21
CA2821009C (en) 2019-03-05
RU2630690C9 (ru) 2017-12-28
KR20200029639A (ko) 2020-03-18
EP2651965B1 (en) 2018-12-12
HK1243633A1 (zh) 2018-07-20
US20140142033A1 (en) 2014-05-22
MY192981A (en) 2022-09-20
JP2019123712A (ja) 2019-07-25
BR112013014890B1 (pt) 2023-10-24
MX2013006831A (es) 2014-10-14
AU2011342284B2 (en) 2017-02-16
SI2651965T1 (sl) 2019-03-29
EP2651965A1 (en) 2013-10-23
JP6144627B2 (ja) 2017-06-07
JP2014505035A (ja) 2014-02-27
SG191069A1 (en) 2013-07-31
CN107496902A (zh) 2017-12-22
KR102011339B1 (ko) 2019-08-16
KR20190002731A (ko) 2019-01-08
US9200038B2 (en) 2015-12-01
JP2017128577A (ja) 2017-07-27
CN103443119B (zh) 2017-09-22
US9714271B2 (en) 2017-07-25
KR102305423B1 (ko) 2021-09-27
EP2651965A4 (en) 2017-08-09
TR201900128T4 (tr) 2019-02-21
MX353720B (es) 2018-01-25
BR112013014890A2 (pt) 2020-08-04
IL226792A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
HRP20190096T1 (hr) Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3
HK1223835A1 (zh) 濃縮蛋白製劑及其用途
IL229353B (en) Dolestatin derivatives related to unnatural amino acids and medicinal preparations that include them
IL248880A0 (en) Preparations containing r-g-cysteic acid peptides and their uses
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
IL230918A0 (en) Modified proteins and peptides
EP2373679A4 (en) HEPPIDINE MINI PEPTIDES AND METHODS OF USE
EP2545161A4 (en) ENTEROBACTER SP. 638 AND METHOD FOR ITS USE
SI2391620T1 (sl) Z alkilaminom substituiran dicianopiridin in njegova predzdravila estra amino kisline
GB201010557D0 (en) RNA molecules and uses thereof
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
HK1172036A1 (en) Cyclic amino acid molecules and methods of preparing the same
IL188681A0 (en) Pharmaceutical compositions and methods utilizing a d-amino acid
ZA201106665B (en) Products comprising n-phenylpropenoyl amino acid amides and uses thereof
EP2275440A4 (en) GROWTH FACTOR IMITING PEPTIDES AND THEIR USE
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
EP2576587A4 (en) MUTANT NGAL PROTEINS AND USES THEREOF
IL210704A0 (en) Nonimmunosuppresive cyclosporine analogue molecules
EP2513137A4 (en) PEPTIDES DERIVED FROM SAPOSINE-A AND USES THEREOF
HK1168363A1 (en) Novel peptide and use thereof
EP2285827A4 (en) PEPTIDES AND ITS USE
EP2668958A4 (en) CASPOFUNGIN ANALOGS AND APPLICATIONS THEREOF
EP2244725A4 (en) NOVEL PEPTIDES AND PROTEIN AND USE THEREOF
PL392256A1 (pl) N-(Bisfosfonometylo)lizyny oraz sposób ich wytwarzania
IL218428A0 (en) Multi-site modified sp1 ploypeptides and uses thereof